Anemia treatment for children and adults is often a last resort, even for children who are diagnosed with the condition, and the treatments can be difficult to get through a doctor’s office.
But when you’re too sick to breathe, there’s an alternative.
The new treatment that researchers at Emory University are testing might be the answer.
Dr. Eric Johnson, director of the University of Pennsylvania’s Center for the Developmental Disabilities Program, is developing a new vaccine that’s targeted specifically to those with severe and persistent anemia, or the inability to get enough oxygen from their lungs.
This is the same type of condition that causes the common cold and can lead to anemia.
Johnson said that the vaccine will be made from the same compound that causes hemolysis, a chemical breakdown that causes blood to pool in the lungs.
It won’t be able to fight hemolytic anemia directly, but instead will target a protein in the hemoglobin that allows it to work.
This protein helps with the body’s ability to produce oxygen, and can be damaged in anemia-caused cases of blood loss.
It’s important to note that this new vaccine will only be tested in children and their parents.
But the researchers have tested a new version of the vaccine in adults, which is expected to be available for use by 2020.
Johnson, who is also an instructor in medicine at the Emory School of Medicine, said that this vaccine is the first to be tested on people with severe or persistent anemic, and that it could be used to help prevent the spread of the virus in the future.
“This is a real game-changer, and I think this vaccine can be used for the first time to treat adults,” Johnson said.
“It’s very exciting because this is the next step in our journey to create an effective and safer vaccine that can be given to people with chronic lung diseases.”
He said that although he’s confident the vaccine works, it’s still early days.
“There’s a lot more work to be done, and we still need to find out more about the safety and efficacy of the treatment and the safety of this vaccine in people with lung disease,” Johnson added.
The researchers have been working with Dr. Richard Wertheimer, the director of Emory’s Division of Hematology and Blood Disorders, to develop the vaccine.
Wertheimer is also a professor in Emory College of Medicine’s Department of Clinical Biochemistry and Biophysics.
He said that he and Johnson are excited to test the vaccine on adults.
“I think this is an amazing opportunity for us to try to understand what happens to hemoglobin in people who have severe anemia and what can we do to treat this,” Wertheim said.
“I think the results will be exciting for the field.”
“We believe that the vaccines that we have in the lab today, and are currently testing in children, are very promising in the short term,” he continued.
“We hope to be able take this vaccine and use it to help treat people with hemolytics and other diseases that may cause hemolytsis.
We believe that this will be a very important advance for the disease-free generation.”
Wertheim believes that it will be too soon to say how the vaccine would work, but he believes that the treatment would work as well as any other vaccine currently available.
“These vaccines that I’ve tested are very well tolerated,” he said.
He added that this could help explain why people who are not diagnosed with a chronic lung disease are able to take the vaccine without problems.
“We are hopeful that this can be a treatment for people who might not have the disease and who have had very severe symptoms,” Wernheimer said.
The vaccine is currently in clinical trials in New York and other states, and is expected later this year.
It’s unclear how long the new vaccine would be able, though.